Vanda Pharma Q2 2024 GAAP EPS $(0.08) Beats $(0.21) Estimate, Sales $50.474M Beat $47.860M Estimate
Vanda Pharma Q2 2024 GAAP EPS $(0.08) Beats $(0.21) Estimate, Sales $50.474M Beat $47.860M Estimate
Vanda Pharma2024年第二季度GAAP每股收益爲$(0.08)，超出$(0.21)的預期，銷售額爲5047.4萬美元，超過4786萬美元的預期。
Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.21) by 61.9 percent. The company reported quarterly sales of $50.474 million which beat the analyst consensus estimate of $47.860 million by 5.46 percent. This is a 9.59 percent increase over sales of $46.056 million the same period last year.
Vanda Pharma (納斯達克:VNDA) 報告本季每股虧損 $(0.08)，超過分析師共識估計的 $(0.21) 61.9%。該公司報告本季銷售額爲 $50,474,000，比分析師共識估計的 $47,860,000 多出5.46%。這是比去年同期銷售額 $46,056,000 的增長9.59%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。